Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQC2731 in Poorly Controlled Severe Asthma
NCT06829784Phase 3Recruiting
- Sponsor
- Chia Tai Tianqing
- Start
- Mar 2025
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in asthma comparing TQC2731 injection with Placebo (2 arms). Primary endpoint: Annualized incidence of asthma exacerbations at 52 weeks. Started Mar 2025; status: recruiting.
02
Drugs
bosakitug
03
Conditions
asthma
Beyond the preview
Go deeper on NCT06829784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06829784.